JPMorgan Reinstates Teva Pharma (TEVA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Teva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
July 30, 2015 7:06 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $1.43, $0.12 better than the analyst estimate of $1.31. Revenue for the quarter came in at $4.97 billion versus the consensus estimate of $4.9 billion.
Teva Pharma sees FY2015 EPS of $5.15-$5.40, versus prior guidance of $5.05-$5.35 and the consensus of... More
